TERN Live signaler | Maksimer profitt med Getagraph.com

SELG 105630 min ago

@ $6.86

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -28.43%

Forrige signal: feb 9 - 21:54

Forrige signal: Kjøp

Avkastning: -0.72 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	495 961
Gjennomsnittsvolum	896 139
Markedsverdi	317.44M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $-0.360 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.87
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Vivo Opportunity, Llc	Sell	136 255	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	76 346	Common Stock
2024-04-03	Vivo Opportunity, Llc	Sell	103 870	Common Stock
2024-04-01	Vivo Opportunity, Llc	Sell	39 411	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	22 084	Common Stock

INSIDER POWER
68.26
Last 96 transactions
Buy: 25 215 859 \| Sell: 2 318 163

Volum Korrelasjon

Lang: 0.60 (weak)

Kort: -0.48 (neutral)

Signal:(69.062) Neutral

Terns Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.926
EMLD	0.908
ARTEU	0.905
CFFE	0.905
PAIC	0.898
LRMR	0.898
GDST	0.897
ARIZ	0.896
CARG	0.892
LQDA	0.891

10 Mest negative korrelasjoner
BCAB	-0.929
ATAI	-0.923
CUTR	-0.923
SMFL	-0.92
GMAB	-0.919
MYSZ	-0.919
SRAC	-0.916
SPCX	-0.908
VFF	-0.906
NCBS	-0.903

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Terns Pharmaceuticals, Korrelasjon - Valuta/Råvare

-0.04
( neutral )

0.13
( neutral )

0.00
( neutral )

0.01
( neutral )

0.00
( neutral )

0.35
( neutral )

Terns Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2023
Omsetning:	$0
Bruttogevinst:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.03M (0.00 %)
EPS:	$-1.670

FY	2021
Omsetning:	$1.00M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.